1. Home
  2. JOF vs AGEN Comparison

JOF vs AGEN Comparison

Compare JOF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Japan Smaller Capitalization Fund Inc

JOF

Japan Smaller Capitalization Fund Inc

HOLD

Current Price

$12.63

Market Cap

328.1M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$7.66

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JOF
AGEN
Founded
1990
1994
Country
Japan
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
328.1M
274.8M
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
JOF
AGEN
Price
$12.63
$7.66
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
70.7K
1.4M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
3.33%
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.96
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.14
Revenue Growth
N/A
89.95
52 Week Low
$9.95
$2.71
52 Week High
$12.76
$8.85

Technical Indicators

Market Signals
Indicator
JOF
AGEN
Relative Strength Index (RSI) 64.89 57.42
Support Level $12.13 $2.97
Resistance Level $12.72 $8.76
Average True Range (ATR) 0.14 0.58
MACD 0.00 -0.07
Stochastic Oscillator 90.09 60.69

Price Performance

Historical Comparison
JOF
AGEN

About JOF Japan Smaller Capitalization Fund Inc

Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: